HUM Stock Analysis: A Mixed Outlook Ahead!
🔴 Recommendation: HUM is currently rated as a buy, reflecting a favorable short-term sentiment among investors, despite a backdrop of mixed indicators.
📈 Key Highlights:
Momentum Indicators: A bullish crossover in the StochRSI suggests potential upward price movement, while the stock is trading above the 50-day EMA, indicating a strengthening bullish trend.
Financial Health: A healthy current ratio of 3.57 indicates strong liquidity, although concerns arise from a high debt-to-equity ratio of 1.83 and declining net income.
Institutional Support: High institutional ownership at 96.25% provides stability, but low insider ownership at 0.21% raises red flags regarding management confidence.
⚠️ Caution Flags:
Long-Term Trends: The stock is currently below the 200-day EMA, indicating a strengthening bearish trend that investors should be wary of.
Valuation Concerns: A forward P/E ratio of 17.71 suggests potential overvaluation relative to earnings growth, while year-over-year revenue growth has declined by 0.24%.
As we delve deeper into the details, we will break down the price trends, indicators, financial health, valuation metrics, and more to provide a comprehensive analysis of HUM stock. Stay tuned! 👇
HUM Price Analysis
| Positive Momentum Signals | Negative Momentum Signals | Hold Momentum Signals |
|---|---|---|
|
|
| Positive Trend Signals | Negative Trend Signals | Hold Trend Signals |
|---|---|---|
|
|
|
HUM stock presents a mixed outlook, characterized by both positive and negative indicators. Currently, the stock is rated as a buy, reflecting a favorable short-term sentiment among investors.
On the positive side, momentum indicators are showing a bullish crossover in the StochRSI, suggesting upward price movement. The stock is positioned closer to support, which may provide a cushion against potential declines. Additionally, trend indicators are largely favorable, with the price trading above the 50-day EMA, indicating a bullish trend that is strengthening. The On-Balance Volume (OBV) is also increasing, supported by high volume, which typically signals strong buying interest. Furthermore, the Supertrend indicator confirms a bullish trend, as the price remains above it.
However, caution is warranted due to some negative trend indicators. Notably, the price is currently below the 200-day EMA, which indicates a bearish trend that is also strengthening. This divergence between short-term bullish signals and long-term bearish trends suggests that while there may be opportunities for gains in the near term, the overall market sentiment could be less favorable.
In summary, while HUM stock shows promising short-term momentum and bullish indicators, the underlying bearish trend indicated by the 200-day EMA cannot be ignored. Investors should approach with caution, considering a buy position but remaining vigilant about potential market corrections.
HUM Fundamental Analysis
HUM’s recent financial performance presents a mixed picture, with several concerning indicators that potential investors should carefully consider.
The company’s **net income** for the most recent period stands at **$679 million**, but it has experienced a **year-over-year decline**, raising significant concerns about its future profitability. Additionally, the **debt-to-equity ratio** is notably high at **1.83**, indicating substantial financial leverage and potential risk. On a more positive note, the **current ratio** of **3.57** suggests a healthy liquidity position, indicating that HUM can comfortably cover its short-term liabilities. However, the **cash to total assets ratio** is low at **0.18**, which may reflect limited financial flexibility and increased vulnerability to economic shocks.
In terms of **valuation**, the **forward P/E ratio** of **17.71** may imply that the stock is overvalued relative to its earnings growth potential. The **price-to-sales ratio** of **0.38** indicates that the stock is trading at a low valuation compared to its revenue, but this could also reflect market skepticism regarding future growth prospects.
When examining **growth and profitability**, HUM faces challenges, with a **year-over-year revenue growth** of **-0.24%**, indicating a decline in revenue that could negatively impact the stock price. Furthermore, **earnings growth** is negative at **-26.50%**, raising alarms about the company’s ability to generate profits moving forward. While the **operating margin** is an impressive **100.00%**, the **net profit margin** is low at **2.30%**, suggesting difficulties in controlling costs.
Regarding **shareholder information**, the **average ordinary shares outstanding** is **122,028,797**, which could lead to potential dilution of earnings per share if new shares are issued. Conversely, the **average treasury shares** of **76,667,132** may indicate management’s confidence in the company’s future prospects through share buybacks.
The **income statement** reveals that total revenue for the most recent period was **$29.54 billion**, showcasing a substantial revenue base. However, **net interest income** is negative at **$168 million**, indicating that the company is paying more in interest on its debts than it is earning on its assets, which could further strain profitability.
On the **balance sheet**, the **average net debt** is high at **$6.93 billion**, warranting further investigation into its impact on financial flexibility. The **average total debt** of **$12.25 billion** raises concerns about the company’s ability to service its debt obligations, although the **average tangible book value** of **$6.68 billion** indicates a solid net worth after liabilities are deducted.
In terms of **cash flow**, the **free cash flow** is negative at **-$9.92 billion**, raising significant concerns about the company’s ability to fund operations and invest in growth. However, the **average capital expenditures** of **$1.11 billion** suggest that the company is still investing in growth and expansion. Additionally, positive net cash from financing activities of **$5.51 billion** indicates that the company is raising capital, which could be utilized for growth or debt reduction.
Overall, while there are some positive indicators such as efficient operations and a healthy current ratio, the negative trends in revenue and earnings growth, along with high debt levels, suggest caution for potential investors.
Financial Health
🔴 Net Income for the most recent period was $679 million, but year-over-year net income decreased, raising concerns about future profitability.
🔴 The Debt-to-Equity Ratio is high at 1.83, indicating significant financial leverage and potential risk.
🟢 Current Ratio of 3.57 suggests a healthy liquidity position, indicating the company can cover its short-term liabilities comfortably.
🔴 Cash to Total Assets Ratio is low at 0.18, which may indicate limited financial flexibility and vulnerability to economic shocks.
Valuation
🔴 Forward P/E ratio of 17.71 may suggest the stock is overvalued relative to its earnings growth potential.
🔴 Price-to-Sales Ratio of 0.38 indicates the stock is trading at a low valuation compared to its revenue, but this could also reflect market skepticism about future growth.
Growth and Profitability
🔴 Year-over-year revenue growth was -0.24%, indicating a decline in revenue, which could negatively impact the stock price.
🔴 Earnings growth is negative at -26.50%, raising concerns about the company’s ability to generate profits in the future.
🟢 Operating Margin of 100.00% suggests efficient operations, but the low Net Profit Margin of 2.30% indicates challenges in controlling costs.
Shareholder Information
🔴 Average Ordinary Shares Outstanding is 122,028,797, which could lead to dilution of earnings per share if new shares are issued.
🟢 Average Treasury Shares of 76,667,132 could indicate management’s confidence in the company’s future prospects through share buybacks.
Income Statement
🟢 Total Revenue for the most recent period was $29.54 billion, indicating a substantial revenue base.
🔴 Net Interest Income was negative at $168 million, suggesting the company is paying more in interest on its debts than it is earning on its assets.
🔴 Interest Expense was also $168 million, which could further strain profitability.
Balance Sheet
🔴 Average Net Debt is high at $6.93 billion, warranting further investigation into its impact on financial flexibility.
🔴 Average Total Debt of $12.25 billion raises concerns about the company’s ability to service its debt obligations.
🟢 Average Tangible Book Value of $6.68 billion indicates a solid net worth after liabilities are deducted.
Cashflow
🔴 Free Cash Flow is negative at -$9.92 billion, raising concerns about the company’s ability to fund operations and invest in growth.
🟢 Average Capital Expenditures of $1.11 billion suggest the company is investing in growth and expansion.
🟢 Positive net cash from financing activities of $5.51 billion indicates the company is raising capital, which could be used for growth or debt reduction.
Overall, while there are some positive indicators such as efficient operations and a healthy current ratio, the negative trends in revenue and earnings growth, along with high debt levels, suggest caution for potential investors.
HUM News Analysis
Humana (HUM) is showing a mix of positive developments and some challenges that could impact its stock performance in the near term.
Summary of Humana news indicates a generally positive outlook for the company, driven by new partnerships and recognition in the healthcare sector. However, the recent settlement of a whistleblower lawsuit raises concerns about potential financial implications. Investors should weigh these factors carefully.
🟢 Humana (HUM) has partnered with Evergreen Nephrology to improve health outcomes, which could enhance its service offerings and attract more patients.
🟢 The introduction of a specialized care program for kidney disease patients demonstrates Humana’s commitment to addressing specific health needs, potentially leading to better patient retention and satisfaction.
🟢 Humana’s CenterWell Home Health has launched its 20th food fundraising drive, showcasing its community engagement and corporate social responsibility efforts.
🟢 Recognition by PEOPLE Magazine as one of the Top “100 Companies That Care” enhances Humana’s brand image and could attract socially conscious investors.
🔴 However, the company recently settled a whistleblower lawsuit related to Medicare Part D fraud allegations for $90 million, which may impact its financial standing and investor confidence.
🔴 Additionally, concerns raised by S&P regarding Medicare Advantage potentially leading to lower hospital credit ratings could pose risks to Humana’s business model.
HUM Holders Analysis
The financial health of HUM shows a mixed outlook, with significant institutional ownership but low insider confidence. This suggests caution for potential investors in the upcoming month.
🔴 HUM has a very low insider ownership at **0.21%**, indicating a lack of confidence from company management. This could be a red flag for potential investors as it suggests that insiders may not believe strongly in the company’s future performance.
🟢 On the positive side, institutional ownership is high at **96.25%**, which reflects strong interest from large investors. This could provide some stability, but it also raises concerns about volatility if these institutions decide to sell.
🟡 The number of institutional holders is substantial at **1409**, indicating a diversified ownership structure. This is generally a positive sign, as it suggests that many institutions have confidence in the company.
🔴 Recent insider transactions show no purchases and a significant amount of selling, which raises concerns about the company’s future prospects. The lack of insider buying could indicate that executives do not foresee a strong performance in the near term.
🔴 The overall sentiment from insider transactions is negative, with no recent purchases and several sales, which could further indicate a lack of confidence in the stock’s future performance.
HUM Analyst Ratings
The analyst ratings for HUM show a mixed sentiment, with a notable number of hold ratings. In the last month, there were 7 strong buy ratings, 5 buy ratings, 7 hold ratings, and no sell or strong sell ratings. This indicates a generally positive outlook, but the presence of multiple hold ratings suggests some analysts are cautious. 🟡
In the past three months, the trend has been relatively stable, with a slight increase in buy recommendations. The recent upgrades from firms like Oppenheimer and TD Cowen to buy and outperform respectively, support a more optimistic view. However, the lack of strong sell ratings indicates that analysts are not overly bearish on the stock.
🟢 Given the current analyst sentiment and the absence of negative ratings, it is likely that HUM will see moderate performance over the next month. A forecasted price range could be between 5% to 10% increase based on the current ratings and market conditions. However, the medium confidence level suggests that investors should remain vigilant and consider market fluctuations.
HUM Economic Analysis
Based on the US economic and market data:
🔴 The unemployment rate has increased to 4.3%, up from 4.1% in the previous month, indicating potential weakness in the labor market which could lead to reduced consumer spending. This is a negative sign for Humana as it may affect their insurance product sales.
🟡 Retail sales have shown a slight increase, but the overall growth is modest. This suggests that while there is some consumer demand, it may not be strong enough to significantly boost Humana’s revenues in the short term.
🔴 The recent CPI data indicates inflationary pressures remain, with the Federal Funds Rate at 5.33%. This could lead to increased operational costs for Humana, impacting profit margins.
🟢 Despite these challenges, Humana’s diversified offerings in healthcare plans and services position it well to weather economic fluctuations. The company’s strong market presence and contracts with Medicare and Medicaid provide a stable revenue base.
🔴 The trailing PE ratio of 24.95 suggests that Humana’s stock may be overvalued compared to its earnings growth, especially given the recent earnings growth decline of -26.5%. This could deter potential investors.
Overall, the combination of rising unemployment, inflationary pressures, and modest retail sales growth presents a challenging environment for Humana in the coming month. The stock may experience volatility, and investors should be cautious.
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
